WO2011015602A3 - Biomarqueurs du cancer du poumon - Google Patents

Biomarqueurs du cancer du poumon Download PDF

Info

Publication number
WO2011015602A3
WO2011015602A3 PCT/EP2010/061354 EP2010061354W WO2011015602A3 WO 2011015602 A3 WO2011015602 A3 WO 2011015602A3 EP 2010061354 W EP2010061354 W EP 2010061354W WO 2011015602 A3 WO2011015602 A3 WO 2011015602A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
managing
cancer
monitoring
cancer biomarkers
Prior art date
Application number
PCT/EP2010/061354
Other languages
English (en)
Other versions
WO2011015602A2 (fr
Inventor
Mariana Guergova-Kuras
Istvan Kurucz
Janos Kadas
William Hempel
Nadège TARDIEU
Carole Malderes-Bloes
Anne Jullien
Yann Kieffer
Laszlo Takacs
Original Assignee
Biosystems International Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosystems International Sas filed Critical Biosystems International Sas
Priority to CA2769406A priority Critical patent/CA2769406A1/fr
Priority to EP10739934A priority patent/EP2462164A2/fr
Publication of WO2011015602A2 publication Critical patent/WO2011015602A2/fr
Publication of WO2011015602A3 publication Critical patent/WO2011015602A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a pour objet des compositions et des méthodes de détection, de gestion ou de surveillance du cancer. L'invention concerne également des anticorps spécifiques pour marqueurs du cancer, des compositions et des puces contenant ceux-ci, ainsi que leurs utilisations pour la détection, la gestion, la surveillance, l'imagerie ou le traitement du cancer, ainsi que pour le développement de médicaments. L'invention est particulièrement adaptée à la détection, à la gestion ou à la surveillance du cancer du poumon chez les sujets humains.
PCT/EP2010/061354 2009-08-04 2010-08-04 Biomarqueurs du cancer du poumon WO2011015602A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2769406A CA2769406A1 (fr) 2009-08-04 2010-08-04 Biomarqueurs du cancer du poumon
EP10739934A EP2462164A2 (fr) 2009-08-04 2010-08-04 Biomarqueurs du cancer du poumon

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23105109P 2009-08-04 2009-08-04
US61/231,051 2009-08-04
US28974509P 2009-12-23 2009-12-23
US61/289,745 2009-12-23

Publications (2)

Publication Number Publication Date
WO2011015602A2 WO2011015602A2 (fr) 2011-02-10
WO2011015602A3 true WO2011015602A3 (fr) 2011-05-26

Family

ID=42951214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/061354 WO2011015602A2 (fr) 2009-08-04 2010-08-04 Biomarqueurs du cancer du poumon

Country Status (3)

Country Link
EP (1) EP2462164A2 (fr)
CA (1) CA2769406A1 (fr)
WO (1) WO2011015602A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107356761A (zh) * 2016-05-09 2017-11-17 上海华盈生物医药科技有限公司 接骨木凝集素及结合珠蛋白相关蛋白的用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0915515D0 (en) 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
ES2701075T3 (es) * 2011-07-01 2019-02-20 Univ Pennsylvania Anticuerpos antiproperdina y usos de estos
EP2822573B1 (fr) * 2012-03-09 2017-08-16 UCL Business Plc. Traitement contre le cancer
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
CN103926413A (zh) * 2014-04-28 2014-07-16 刘红莉 一种用尿液进行癌症快速检测的试剂条的制备方法
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
KR102078310B1 (ko) * 2015-09-11 2020-02-19 주식회사 압타머사이언스 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
GB201702792D0 (en) * 2017-02-21 2017-04-05 Queens Univ Of Belfast A new biomarker for preeclampsia
CN111148844A (zh) 2017-09-01 2020-05-12 韦恩生物科技股份公司 鉴定和使用糖肽作为诊断和治疗监测的生物标记物
EP3798227A4 (fr) * 2018-05-09 2022-03-02 Good T Cells, Inc. Épitope d'antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci
KR20210073547A (ko) * 2018-10-09 2021-06-18 세키스이 메디칼 가부시키가이샤 류신 리치 α2 글리코 단백질 조성물
EP3671210A1 (fr) * 2018-12-21 2020-06-24 Biosystems International KFT Biomarqueurs épitomiques de protéines du cancer du poumon
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
WO2024050524A1 (fr) * 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions et procédés de direction de l'apolipoprotéine l1 en vue d'induire la mort de cellules de mammifère

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
WO2008114917A1 (fr) * 2007-03-21 2008-09-25 Protan Bio Co., Ltd. Fragments de kallikréine dans le plasma comme biomarqueurs diagnostiques pour le cancer du poumon
US20090035875A1 (en) * 2006-01-25 2009-02-05 Jemmerson Ronald R Cytochrome C And Leucine-Rich Alpha-2-Glycoprotein-1 Assays, Methods, And Antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS5441129A (en) 1977-09-07 1979-04-02 Minolta Camera Co Ltd Modified gauss type photographic lens
FR2724182B1 (fr) 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
US20090035875A1 (en) * 2006-01-25 2009-02-05 Jemmerson Ronald R Cytochrome C And Leucine-Rich Alpha-2-Glycoprotein-1 Assays, Methods, And Antibodies
WO2008114917A1 (fr) * 2007-03-21 2008-09-25 Protan Bio Co., Ltd. Fragments de kallikréine dans le plasma comme biomarqueurs diagnostiques pour le cancer du poumon

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; April 1983 (1983-04-01), TAKADA K ET AL: "[Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases].", XP002630003, Database accession no. NLM6602233 *
GAN NO RINSHO. JAPAN JOURNAL OF CANCER CLINICS APR 1983 LNKD- PUBMED:6602233, vol. 29, no. 4, April 1983 (1983-04-01), pages A - 19 , 293, ISSN: 0021-4949 *
HEO SUN-HEE ET AL: "Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS.", PROTEOMICS DEC 2007 LNKD- PUBMED:17963278, vol. 7, no. 23, December 2007 (2007-12-01), pages 4292 - 4302, XP009140371, ISSN: 1615-9853 *
HOAGLAND LUKE F M 4TH ET AL: "Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.", CANCER 15 NOV 2007 LNKD- PUBMED:17918261, vol. 110, no. 10, 15 November 2007 (2007-11-15), pages 2260 - 2268, XP009140372, ISSN: 0008-543X *
MORGAN B P ET AL: "Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 134, no. 1-2, 31 October 1983 (1983-10-31), pages 85 - 94, XP023396301, ISSN: 0009-8981, [retrieved on 19831031], DOI: DOI:10.1016/0009-8981(83)90187-0 *
OKANO TETSUYA ET AL: "Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis.", PROTEOMICS JUL 2006 LNKD- PUBMED:16767791, vol. 6, no. 13, July 2006 (2006-07-01), pages 3938 - 3948, XP009140370, ISSN: 1615-9853 *
See also references of EP2462164A2 *
WEIVODA S ET AL: "ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL LNKD- DOI:10.1016/J.JIM.2008.03.004, vol. 336, no. 1, 20 July 2008 (2008-07-20), pages 22 - 29, XP022682287, ISSN: 0022-1759, [retrieved on 20080404] *
YEE JOHN ET AL: "Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 JUN 2009 LNKD- PUBMED:19414677, vol. 27, no. 17, 10 June 2009 (2009-06-10), pages 2787 - 2792, XP009140373, ISSN: 1527-7755 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107356761A (zh) * 2016-05-09 2017-11-17 上海华盈生物医药科技有限公司 接骨木凝集素及结合珠蛋白相关蛋白的用途

Also Published As

Publication number Publication date
CA2769406A1 (fr) 2011-02-10
EP2462164A2 (fr) 2012-06-13
WO2011015602A2 (fr) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2011015602A3 (fr) Biomarqueurs du cancer du poumon
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2012054638A3 (fr) Systèmes et procédés nmr pour la détection d'analytes
WO2012031008A3 (fr) Matières biologiques liées au cancer dans des microvésicules
EP4303584A3 (fr) Procédés de détection de signatures de maladies ou pathologies dans des liquides biologiques
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
WO2009123737A3 (fr) Détection avancée d'une sepsie
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
WO2013039477A8 (fr) Procédés non invasifs de détection de molécules cibles
WO2009114603A3 (fr) Analyse de confiance d'un irm de tenseur de diffusion
WO2012021407A3 (fr) Biomarqueurs pour accident vasculaire cérébral
WO2013066369A3 (fr) Procédés de détection de maladie du greffon contre l'hôte
WO2010027903A8 (fr) Diagnostic du cancer du poumon
WO2009085234A3 (fr) Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
WO2011045080A3 (fr) Anticorps monoclonaux contre la progastrine et leurs utilisations
EP3054299A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
WO2010091049A3 (fr) Diagnostic et traitement du cancer
GB0718967D0 (en) Peptide imaging agents
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
WO2011002834A3 (fr) Compositions et procédés de diagnostic et de traitement du diabète de type i
WO2010097186A8 (fr) Utilisation de s-erbb-3 comme marqueur des cancers
WO2011146945A3 (fr) Kinase alk et ros dans le cancer
WO2011087709A3 (fr) Translocations d'eml4-alk dans le cancer pulmonaire
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10739934

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2010739934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010739934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2769406

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE